Champions Oncology, Inc.（CSBR）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

42/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

65

Undervalued

動能

32

Weakening

情緒

40

Bearish

風險韌性

38

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Robert Brainin
上市以來: 2007年2月2日
僱員: 214

市場位置

日內區間

目前US$4.9601，

US$4.9126US$5.24

52週區間

目前US$4.9601，

US$4.83US$8.74

開盤價: US$5.24
前收盤價: US$5.18
成交量: 8111; 0.88× 平均值
平均成交量: 9184; 日均成交量
市值: 6891.35萬 USD
貝塔: 0.41; 市場參考 1
50天平均值: US$5.7822; 低於平均水平-14.22%
200天平均值: US$6.1764; 低於平均水平-19.69%

財務數據

財務快照

估值與收益率

本益比（TTM）: -62×
股價淨值比（TTM）: 17.42×
股價營收比（TTM）: 1.16×
股息率: 0.00%

獲利能力和效率

毛利率: 48.00%
營業利益率: -1.92%
淨利潤率: -1.98%

財務健康

負債權益比: 1.17×

財報歷史與展望

EPS優於預期率: 64%; 優於預期7次、低於預期4次、符合預期0次
平均EPS意外幅度: +342.12%; 11 類似報告
最新每股收益結果: 0.01; 預估-0.05 · 優於預期120.00%

EPS：實際值與預估值

近期已公布業績

實際值預估值

營收：實際值與預估值

近期已公布業績

實際值預估值

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

評級分佈

7項評級

強力買進00%

買進571%

持有229%

賣出00%

強力賣出00%

CSBR 訊息

zacks.com2026年7月30日

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.

閱讀原始碼

seekingalpha.com2026年7月27日

Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript

閱讀原始碼

marketbeat.com2026年7月27日

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services…

閱讀原始碼

accessnewswire.com2026年7月27日

Champions Oncology Reports Record Annual Revenue of $59 Million

Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models…

閱讀原始碼

zacks.com2026年7月23日

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

閱讀原始碼